Novel screening test for celiac disease using peptide functionalised gold nanoparticles

Table 1 Comparison of the patient samples analysis using the AuNP-peptide-anti-gliadin test with previously existing histology and serological¹ results

Volunteer	Histology	tTG-IgA	DGP-IgG	AuNP-peptide-AGA test
n.1	CD	1 (< 4)	3 (< 20)	CD positive
n.21	Non-CD	0.1 (0-6)	0.2 (0-6)	CD positive
n.3	CD	> 100 (< 4)	33 (< 20)	CD positive
n.4	CD	121 (< 20)		CD positive
n.5	CD	> 100 (< 4)	> 100 (< 20)	CD positive
n.6	CD	217 (< 5)	> 150 (< 20)	CD positive
n.72	CD	13 (0-6)	23 (0-6)	CD negative
n.8	CD	> 100 (< 5)	> 100 (< 20)	CD positive
n.9	CD	11 (0-6)	1.4 (0-6)	CD positive
n.10	CD	9 (< 4)	97 (< 20)	CD positive
n.11	CD	18.2 (0 < 20)	3 (0.20)	CD positive
n.12	CD	16 (0-20)	7 (< 20)	CD positive
n.13	Non-CD	4 (0-20)		Non-CD
n.14	CD	47 (< 5)	86 (< 5)	CD positive
n.152	CD	74 (0-20)		CD negative
n.16	CD	145 (0-20)		CD positive
n.17	CD	57 (< 4)	93 (< 20)	CD positive
n.18	CD	149 (<20)	63 (< 20)	CD positive
n.19	CD	> 100 (< 4)	> 100 (< 20)	CD positive
n.201	Non-CD	3.8 (< 6)	37 (< 6)	CD positive
n.21	Non-CD	< 5 (< 5)	< 20 (< 20)	Non-CD
n.22	CD	180 (0-6)	21 (0-6)	CD positive
n.23	CD	20 (0-6)	8.1 (0-6)	CD positive

¹False positive based on histology and tTG antibody titre,

²False negative based on histology and tTG antibody titre. Serology tTG (Tissue transglutaminase), deamidated gliadin peptides (deaminated gliadin peptides) results are indicated as IgA or IgG levels followed by normal reference ranges in brackets.